Biotech and Pharmaceuticals
Weight loss and hair loss: The growing hair treatment market from GLP-1s
When Branneisha Cooper first began taking GLP-1 injection Mounjaro in late 2022, she heard online that she could experience temporary hair thinning and prepared for the worst. But it would take about a year before she began noticing her hair falling out in clumps. Cooper said it was especially shocking because she has always had […]
Read More
AstraZeneca stock falls after FDA panel votes against new cancer drug
Shares of AstraZeneca turned lower Friday after U.S. regulatory advisors voted against approving its experimental cancer drug. An advisory panel for the U.S. Food and Drug Administration late Thursday voted 6-3 against AstraZeneca’s oral drug camizestrant intended for the treatment of a type of breast cancer tumor, citing concerns around trial design. The FDA generally […]
Read More
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Thursday proposed excluding the active ingredients in Novo Nordisk and Eli Lilly‘s blockbuster obesity and diabetes medications from the list of drugs that outsourcing facilities can use for compounding […]
Read More
More than 20,000 people are taking Eli Lilly’s weight loss pill Foundayo, CEO says
More than 20,000 people have started taking Eli Lilly‘s GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday. The FDA approved Lilly’s once-daily pill Foundayo earlier this month, making it the second oral GLP-1 drug behind Novo Nordisk’s Wegovy pill. Investors have been closely tracking […]
Read More
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IMF) and World Bank Spring meetings in Washington, DC, US, on Friday, April 17, 2026. Aaron Schwartz | Bloomberg | Getty Images Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past […]
Read More
UK’s biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
AstraZeneca and GSK, the U.K.’s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday. Source
Read More
Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs
Pharma thinks it’s found the next frontier in preventing heart attacks. Novartis, Amgen and Eli Lilly are among the drugmakers betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology. All three of the pharmaceutical giants are in late-stage trials to test whether drugs that cut Lp(a) […]
Read More
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. Spencer Grant | Universal Images Group | Getty Images Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval […]
Read More
Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss
Regeneron Pharmaceuticals will make its newly approved gene therapy for a rare, genetic form of hearing loss available for free in the U.S. The company hasn’t yet decided how much it will charge in other countries, Regeneron CEO Leonard Schleifer told CNBC on Friday. “We haven’t set a price yet, but they should pay their […]
Read More
FDA fast-tracks psychedelic drug research following Trump executive order
FILE PHOTO: Psilocybin or “magic mushrooms” are seen in an undated photo provided by the U.S. Drug Enforcement Agency (DEA) in Washington, U.S. May 7, 2019. DEA | Reuters The U.S. Food and Drug Administration on Friday announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. That […]
Read More